167 related articles for article (PubMed ID: 23377984)
1. Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.
Zhao J; Wu XY; Ling XH; Lin ZY; Fu X; Deng YH; He HC; Zhong W
Med Oncol; 2013 Mar; 30(1):465. PubMed ID: 23377984
[TBL] [Abstract][Full Text] [Related]
2. E2F5 promotes prostate cancer cell migration and invasion through regulation of TFPI2, MMP-2 and MMP-9.
Karmakar D; Maity J; Mondal P; Shyam Chowdhury P; Sikdar N; Karmakar P; Das C; Sengupta S
Carcinogenesis; 2020 Dec; 41(12):1767-1780. PubMed ID: 32386317
[TBL] [Abstract][Full Text] [Related]
3. The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.
Li SM; Wu HL; Yu X; Tang K; Wang SG; Ye ZQ; Hu J
J Exp Clin Cancer Res; 2018 Sep; 37(1):219. PubMed ID: 30185212
[TBL] [Abstract][Full Text] [Related]
4. CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis.
Qi JC; Yang Z; Lin T; Ma L; Wang YX; Zhang Y; Gao CC; Liu KL; Li W; Zhao AN; Shi B; Zhang H; Wang DD; Wang XL; Wen JK; Qu CB
J Exp Clin Cancer Res; 2021 Jan; 40(1):2. PubMed ID: 33390186
[TBL] [Abstract][Full Text] [Related]
5. Deregulated E2F5/p38/SMAD3 Circuitry Reinforces the Pro-Tumorigenic Switch of TGFβ Signaling in Prostate Cancer.
Majumder S; Bhowal A; Basu S; Mukherjee P; Chatterji U; Sengupta S
J Cell Physiol; 2016 Nov; 231(11):2482-92. PubMed ID: 26919443
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].
Zeng X; Wu SF; Xu Q; Xiao Y; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):523-8. PubMed ID: 17134545
[TBL] [Abstract][Full Text] [Related]
8. Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors.
Polanowska J; Le Cam L; Orsetti B; Vallés H; Fabbrizio E; Fajas L; Taviaux S; Theillet C; Sardet C
Genes Chromosomes Cancer; 2000 May; 28(1):126-30. PubMed ID: 10738311
[TBL] [Abstract][Full Text] [Related]
9. Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer.
Vasmatzis G; Kosari F; Murphy SJ; Terra S; Kovtun IV; Harris FR; Zarei S; Smadbeck JB; Johnson SH; Gaitatzes AG; Therneau TM; Rangel LJ; Knudson RA; Greipp P; Sukov WR; Knutson DL; Kloft-Nelson SM; Karnes RJ; Cheville JC
Mayo Clin Proc; 2019 Jan; 94(1):27-36. PubMed ID: 30611450
[TBL] [Abstract][Full Text] [Related]
10. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.
Reiter RE; Sato I; Thomas G; Qian J; Gu Z; Watabe T; Loda M; Jenkins RB
Genes Chromosomes Cancer; 2000 Jan; 27(1):95-103. PubMed ID: 10564591
[TBL] [Abstract][Full Text] [Related]
11. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
12. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
13. SOXs in human prostate cancer: implication as progression and prognosis factors.
Zhong WD; Qin GQ; Dai QS; Han ZD; Chen SM; Ling XH; Fu X; Cai C; Chen JH; Chen XB; Lin ZY; Deng YH; Wu SL; He HC; Wu CL
BMC Cancer; 2012 Jun; 12():248. PubMed ID: 22703285
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
15. Identification of tumor suppressive role of microRNA-132 and its target gene in tumorigenesis of prostate cancer.
Li SL; Sui Y; Sun J; Jiang TQ; Dong G
Int J Mol Med; 2018 Apr; 41(4):2429-2433. PubMed ID: 29393367
[TBL] [Abstract][Full Text] [Related]
16. Expression of SOCSs in human prostate cancer and their association in prognosis.
Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
[TBL] [Abstract][Full Text] [Related]
17. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.
Patil MA; Gütgemann I; Zhang J; Ho C; Cheung ST; Ginzinger D; Li R; Dykema KJ; So S; Fan ST; Kakar S; Furge KA; Büttner R; Chen X
Carcinogenesis; 2005 Dec; 26(12):2050-7. PubMed ID: 16000397
[TBL] [Abstract][Full Text] [Related]
18. 8q24 allelic imbalance and MYC gene copy number in primary prostate cancer.
Chen H; Liu W; Roberts W; Hooker S; Fedor H; DeMarzo A; Isaacs W; Kittles RA
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):238-43. PubMed ID: 20634801
[TBL] [Abstract][Full Text] [Related]
19. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
20. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.
Savinainen KJ; Linja MJ; Saramäki OR; Tammela TL; Chang GT; Brinkmann AO; Visakorpi T
Br J Cancer; 2004 Mar; 90(5):1041-6. PubMed ID: 14997205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
